Johnson & Johnson (NYSE:JNJ) Shares Up 2% – Time to Buy?

Johnson & Johnson (NYSE:JNJ)’s stock price traded up 2% during mid-day trading on Wednesday . The stock traded as high as $256.29 and last traded at $255.7140. 8,619,168 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 8,454,772 shares. The stock had previously closed at $250.61.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted De Novo authorization for J&J’s OTTAVA robotic surgical system, giving the company a new entry into the U.S. soft-tissue surgical robotics market and raising expectations for future medtech revenue. FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System
• Positive Sentiment: J&J also reported strong late-stage data for its multiple myeloma portfolio: TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma, strengthening confidence in the company’s oncology pipeline. TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
• Positive Sentiment: Those cancer-trial results were also highlighted by the company as another sign that its T-cell therapy portfolio is advancing earlier in treatment, which could support longer-term growth and sentiment around J&J’s pharma franchise. TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
• Neutral Sentiment: J&J’s recent Q2 earnings beat and bullish 2026 outlook continue to keep investors focused on its strong fundamentals, while dividend-focused articles are reinforcing the stock’s appeal as a large, defensive income name. ETFs to Buy Post JNJ’s Q2 Earnings Beat & Bullish 2026 Outlook
• Negative Sentiment: On the risk side, a federal judge cast doubt on about 69,000 talc-related cancer claims, but the litigation remains a major overhang and could still create headline risk for J&J. US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. The Goldman Sachs Group restated a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. Daiwa Securities Group upped their target price on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday, April 16th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research note on Wednesday, April 15th. Finally, JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.30.

Johnson & Johnson Trading Up 1.5%

The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $624.29 billion, a PE ratio of 30.05, a price-to-earnings-growth ratio of 2.43 and a beta of 0.24. The company’s 50-day simple moving average is $241.98 and its 200 day simple moving average is $236.13.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The firm had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter last year, the firm earned $2.77 EPS. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.68 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insider Buying and Selling

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds have recently bought and sold shares of the business. Naples Global Advisors LLC lifted its holdings in Johnson & Johnson by 0.6% during the second quarter. Naples Global Advisors LLC now owns 52,184 shares of the company’s stock valued at $13,253,000 after purchasing an additional 291 shares in the last quarter. Total Clarity Wealth Management Inc. grew its position in shares of Johnson & Johnson by 40.8% in the second quarter. Total Clarity Wealth Management Inc. now owns 5,699 shares of the company’s stock valued at $1,447,000 after purchasing an additional 1,650 shares in the last quarter. Signaturefd LLC grew its holdings in Johnson & Johnson by 3.0% in the 2nd quarter. Signaturefd LLC now owns 72,573 shares of the company’s stock valued at $18,431,000 after buying an additional 2,140 shares in the last quarter. Crewe Advisors LLC increased its position in Johnson & Johnson by 14.1% during the second quarter. Crewe Advisors LLC now owns 3,263 shares of the company’s stock worth $829,000 after purchasing an additional 404 shares during the last quarter. Finally, Cascade Investment Group Inc. raised its position in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Cascade Investment Group Inc. now owns 5,569 shares of the company’s stock valued at $1,414,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.